Analyzing Eloxx Pharmaceuticals (ELOX) and Its Peers

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, dividends and risk.

Analyst Recommendations

This is a summary of current ratings for Eloxx Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, indicating a potential upside of 155.05%. As a group, “Pharmaceuticals” companies have a potential upside of 27.31%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

(Get Free Report)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.